1 citations
,
April 2018 in “Journal of Investigative Dermatology” Simvastatin helps hair regrowth in autoimmune alopecia by directly affecting T cells.
38 citations
,
January 2016 in “Cell Death and Disease” The TCL1 transgenic mouse model is useful for understanding human B-cell leukemia and testing new treatments.
July 2023 in “Skin Research and Technology” Baricitinib combined with other immune therapies may safely and effectively treat severe scalp hair loss.
4 citations
,
December 2024 in “European Journal of Medicinal Chemistry” New pyrazole-based inhibitors show promise for treating metabolic diseases and other conditions.
December 2022 in “International Journal of Molecular Sciences” Afatinib, neratinib, and zanubrutinib could be effective against KRASG12C-mutant tumors.
YH0618 helps reduce chemotherapy-induced hair loss by targeting specific proteins and pathways.
Suppressing ODC activity reduces tumor growth in hair follicles.
17 citations
,
December 1997 in “Transplantation” Tacrolimus can cause hair loss in kidney transplant patients.
June 2024 in “Journal of Clinical Oncology” The combination of TACE and Donafenib is effective and tolerable for treating unresectable liver cancer.
Newly designed proteins can effectively degrade specific proteins in cells, offering a promising alternative for targeted protein degradation.
1 citations
,
February 2022 in “Clinical, Cosmetic and Investigational Dermatology” TDM10842, a thyroid hormone receptor activator, was found to effectively promote hair growth in mice.
July 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is generally safe for alopecia areata patients over 72 months.
93 citations
,
May 2010 in “European Journal of Cancer” BI 2536 had limited effectiveness against several advanced cancers and caused significant side effects.
January 2026 in “Human Mutation” T cell subsets are crucial in kidney cancer, and a new model predicts patient outcomes using key genes.
9 citations
,
October 2019 in “Dermatologic Therapy” Oral tofacitinib has a moderate success rate and is generally safe for treating hair loss in some patients.
4 citations
,
May 2023 in “Cells” Baricitinib and its combination with lonafarnib improve fat cell formation in certain genetic disorders.
1 citations
,
August 2024 in “JAAD Case Reports” Tick bites can cause hair loss similar to alopecia areata, and baricitinib may help regrow hair.
July 2024 in “Journal of Investigative Dermatology” INTASYL is a promising, adaptable RNAi technology for treating skin cancers.
29 citations
,
June 2015 in “Kidney International” Disrupting the Flcn gene in mice causes early kidney cysts and tumors, which can be treated with rapamycin.
June 2023 in “Journal of Clinical Oncology” CDK4/6 inhibitors may cause hair loss in breast cancer patients.
March 2026 in “Journal of Pakistan Association of Dermatologists” Tofacitinib helps hair regrowth in alopecia areata but relapse is common after stopping treatment.
January 2024 in “Revista de la Asociación Colombiana de Dermatología y Cirugía Dermatológica/Revista de la Asociacion Colombiana de Dermatologia y Cirugia Dermatologica” Baricitinib successfully treated severe hair loss.
2 citations
,
November 2024 in “In Silico Pharmacology”
January 2024 in “Skin Research and Technology” Oral tofacitinib may be an effective future treatment for children with severe alopecia areata, but more research is needed.
April 2025 in “Anais Brasileiros de Dermatologia” Abrocitinib effectively treats severe alopecia areata with significant improvement and no side effects.
August 2013 in “Nature Reviews Drug Discovery” New cancer treatments show promise in reducing tumor growth and improving skin regeneration in mice.
Baricitinib helped treat a man's beard hair loss when steroids didn't work.
66 citations
,
June 2021 in “Journal of The American Academy of Dermatology” Baricitinib is effective and safe for treating severe alopecia areata.
1 citations
,
September 2015 Gefitinib treatment led to unexpected hair growth in two lung cancer patients.
22 citations
,
March 2017 in “Transplant Infectious Disease” Leflunomide successfully treated a rare skin condition in a liver transplant patient.